65 citations
,
March 2004 in “Journal of Clinical Investigation” Inhibiting ornithine decarboxylase may help prevent certain skin cancers.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
3 citations
,
June 2025 in “Drug Design Development and Therapy” Targeting glycolysis may help treat PCOS by improving insulin sensitivity and ovarian function.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
3 citations
,
September 2022 in “Cureus” Platelet-rich plasma shows promise for treating various female reproductive health issues but requires more research.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
April 2026 in “UNC Libraries” Pulsed electric field treatment may help shrink untreated liver tumors.
4 citations
,
December 2013 in “British Journal of Dermatology” ESR2 gene linked to female-pattern hair loss.
The treatment was ineffective in humans.
6 citations
,
September 2019 in “Indian Journal of Dermatology” 1 citations
,
September 2021 in “Pharmaceutics” High-dose finasteride may help treat glioblastoma but needs localized delivery for effectiveness.
September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” Cancer prevention has advanced significantly, with some strategies proving successful.
January 2026 in “Journal of Community Medicine and Health Solutions” PP405 shows promise as a new, effective treatment for hair loss with minimal side effects.
32 citations
,
February 1993 in “British Journal of Clinical Pharmacology” Measuring OPC-17116 in hair can reliably indicate drug exposure and timing.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
8 citations
,
April 2014 in “Anti-Cancer Drugs” A hormone linked to collagen helps hair grow back in mice after chemotherapy, and may also prevent bone loss.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
January 2022 in “Research Square (Research Square)” High TSPEAR levels in colorectal cancer predict worse outcomes.
6 citations
,
April 2018 in “Transplantation proceedings” A woman experienced severe side effects from a drug due to a specific genetic variation, suggesting genetic testing could prevent such risks.
July 2024 in “Russian Journal of Child Neurology” Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.
April 2020 in “International journal of reproduction, contraception, obstetrics and gynecology” A postmenopausal woman with hair loss and hirsutism improved after surgery to remove an ovarian tumor.
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.